omnicell

Stifel Nicolaus has upgraded Omnicell (NASDAQ: OMCL) from Hold to Buy and has established a $17 price target.

Piper Jaffray is out with its report today on Omnicell (NASDAQ: OMCL), reiterating Overweight. In a note to clients, Piper Jaffray writes, "We believe companies that invest during downturns do better on the recovery, and that OMCL is set up for a strong recovery after investing heavily in new...

According to Auriga, Omnicell (NASDAQ: OMCL) Buy rating is reiterated. Auriga said that it is reiterating its BUY rating on Omnicell (OMCL) after a day of investor meetings last week. “The company occupies a solid #2 position (23% market share) behind market leader Carefusion (CFN, NR) and...

Piper Jaffray maintained its Overweight rating on Omnicell (NASDAQ: OMCL) in a research report published today. It also left its price target unchanged at $17. In the report, Piper Jaffray states, "The company reported a penny upside on EPS and in-line revenues by continued expansion in gross...

Piper Jaffray is maintaining its Overweight rating and $17 PT on Omnicell, Inc. (NASDAQ: OMCL). According to Piper Jaffray, Omnicell, Inc. reported revenues that beat estimates but missed EPS by a penny mainly due to increased SG&A expenses related to the sales force expansion (58 up from 45...

Cerner Corporation's (NASDAQ: CERN) well-attended user conference highlighted the need for change in healthcare, Piper Jaffray reports. Healthcare reform and accountable care organizations (ACOs) garnered much attention among attendees, who reportedly agree that the formation of ACOs are inevitable...

Auriga USA has reiterated its Buy ratings on the following companies: MetroPCS (NYSE: PCS) price target raised from $11 to $13 Omnicell (NASDAQ: OMCL) price target raised from $15 to $16

Piper Jaffray has published a Health Care Services: Information Technology report with key takeaways which are as follows: "Sharp [Healthcare] is one of about a dozen hospitals that have both Cerner and Allscripts. Getting the two vendors to cooperate has been challenging at times. At the root of...